Compositions and methods for inhibiting microbial adhesion

• US 20080096806A1
• Filed: 11/05/2007
• Published: 04/24/2008
• Est. Priority Date: 04/22/2002
• Status: Abandoned Application

• Current Assignee: Recopharma AB
• Original Assignee: Recopharma AB
• Inventors: Lofling, Jonas, Holgersson, Jan
• Application Number:
  US11/983,007
• Publication Number:
  US 20080096806A1
• Time in Patent Office: Days
• US Class Current: 424/130.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/70596 Molecules with a "CD"-designation not provided for elsewhere
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention provides compositions and methods for treating or preventing microbial infections.

Claims

1. A method for preventing or alleviating a symptom of a Helicobacter pylori infection in a subject in need thereof, the method comprising administering to the subject fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide is glycosylated by an α

1,3 fucosyltransferase and the second polypeptide comprises at least a region of an immunoglobulin polypeptide.

11. The method of claim 1, wherein the first polypeptide is a mucin polypeptide.

12. The method of claim 1, wherein said mucin polypeptide comprises at least a region of a P-selectin glycoprotein ligand-1.

13. The method of claim 12, wherein said mucin polypeptide includes an extracellular portion of a P-selectin glycoprotein ligand-1.

14. The method claim 1, wherein the first polypeptide is a alpha glycoprotein polypeptide.

15. The method of claim 1, wherein the first polypeptide comprises at least a region of an alpha-1-acid glycoprotein.

16. The method of claim 1, wherein the second polypeptide comprises a region of a heavy chain immunoglobulin polypeptide.

17. The method of claim 1, wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.

18. The method of claim 1, wherein the fusion polypeptide is a dimer.

2. A method for preventing or alleviating a symptom peptic acid disease or gastric adenocarcinoma in a subject in need thereof, the method comprising administering to the subject a fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide is glycosylated by an α

1,3 fucosyltransferase and the second polypeptide comprises at least a region of an immunoglobulin polypeptide.

3. The method of claim 2, wherein said peptic disease is a peptic ulcer.

4. A method of decreasing adhesion of a microbe to a cell, the method comprising contacting said microbe with a fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide is glycosylated by an α

1,3 fucosyltransferase and the second polypeptide comprises at least a region of an immunoglobulin polypeptide

5. The method of claim 4, wherein said microbe is contacted in vivo, in vitro or ex vivo.

6. The method of claim 4, wherein said microbe is a bacteria, a virus or a fungus.

7. The method of claim 6, wherein said bacteria is a Helicobacter pylori.

8. The method of claim 6, wherein said cell is gastric mucosal cell.

9. A method of decreasing adhesion of a bacterial toxin to a cell, the method comprising contacting said microbe with a fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide is glycosylated by an α

1,3 fucosyltransferase and the second polypeptide comprises at least a region of an immunoglobulin polypeptide.

10. The method of claim 9, wherein said cell is gastric mucosal cell.